Free Trial
NASDAQ:PASG

Passage Bio Q4 2023 Earnings Report

Passage Bio logo
$5.66 -0.01 (-0.09%)
Closing price 08/7/2025 03:58 PM Eastern
Extended Trading
$5.36 -0.29 (-5.13%)
As of 07:14 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Passage Bio EPS Results

Actual EPS
-$6.00
Consensus EPS
-$8.20
Beat/Miss
Beat by +$2.20
One Year Ago EPS
N/A

Passage Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Passage Bio Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Monday, March 4, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Passage Bio's Q2 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled at 7:15 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Passage Bio Earnings Headlines

Passage Bio (PASG) Projected to Post Quarterly Earnings on Thursday
BREAKING: The House just passed 3 pro-crypto bills!
THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here.
Passage Bio Announces 1-for-20 Reverse Stock Split
PASG Passage Bio, Inc. - Seeking Alpha
See More Passage Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Passage Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Passage Bio and other key companies, straight to your email.

About Passage Bio

Passage Bio (NASDAQ:PASG), a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

View Passage Bio Profile

More Earnings Resources from MarketBeat